Higher patient cost-sharing is associated with a lower likelihood of treatment augmentation in patients with depression who are treated with antidepressants.
Zhun Cao, PhD
Advertisement
Articles by Zhun Cao, PhD
Prior authorization for pregabalin in commercial insurance plans accomplished the objective of lower pregabalin utilization; however, there was no significant decrease in disease-related healthcare costs.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Extension Studies in TPIP Show Promise in PAH, PH-ILD
2
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
3
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5